Cellestia Biotech

Cellestia is a bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.

Cellestia is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders. Cellestia Biotech was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne, Switzerland). Cellestia`s pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decades of research in Prof. Radtke´s laboratory at Swiss Institute for Experimental Cancer Research (ISREC) at EPFL. Prof. Freddy Radtke is an internationally recognized key opinion leader in NOTCH pathway and cancer stem cells research. Dr. Rajwinder Lehal, CSO, has established Cellestia’s drug discovery platform and leading the early development phase of the program for a decade.